Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease

This study (4238 cases, 42380 controls) found risk of MACE in CML patients was similar to those without CML, but may be higher for cerebrovascular and peripheral arterial events. There was no difference in MACE risk among different TKI inhibitors (imatinib, dasatinib, nilotinib)

Source:

Heart